EXCHANGE AGREEMENT THIS  EXCHANGE  AGREEMENT  (the  Agreement)  is  made  as  of  the  31st  day  of DecemberandeffectiveNovember14,2018,byandbetween,ParallaxHealthSciences,Inc.,a Nevadacorporation,(theCompany)andCavalryFundILP,aDelawarelimitedpartnership (the Investor). WHEREAS, the Investor has previously acquired various securities from the Company in theformofconvertiblenoteswithvariousdatesofissuanceassetforthonScheduleI(the Notes). WHEREAS,  the  Company  has  authorized  a  new  series  of  convertible  debenture  due February28,2019intheformofExhibitAhereto,whichwillbeconvertibleintosharesofthe Companys Common Stock, par value $0.001. WHEREAS,subjecttothesatisfactionoftheconditionssetforthherein,theCompany andtheInvestordesiretoenterintoatransactionwhereintheCompanyshallissuetheInvestor the debenture intheamountof$322,411.86 (theDebenture) in exchange for each of the Notes as set forth on Schedule I (the Exchange). NOW,THEREFORE,forgoodandvaluableconsideration,thereceiptandsufficiencyof which are hereby acknowledged, the parties agree as follows:  1. Exchange.  The closing of the Exchange (the Closing) will occur on or before December 31, 2018 (or such later date as the parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date, the Closing Date). On the Closing Date, subject to the terms and conditions of this Agreement, the Investor shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the Securities Act), exchange the Notes for the Debenture. At the Closing, the following transactions shall occur (such transactions in this Section 1, the Exchange): 1.1.      OntheClosingDate,theCompanyshallissuetheDebenturetothe Investor.  Promptly  after  the  Closing  Date,  the  Company  shall  deliver  an  executed  original DebenturetotheInvestor.OntheClosingDate,theInvestorshallbedeemedforallcorporate purposestohavebecometheholderofrecordoftheDebentureandshallhavetherightto convert  the  Debenture,  irrespective  of  the  date  the  Company  delivers  the  Debenture  to  the Investor. 1.2.      UponreceiptoftheDebentureinaccordancewithSection1.1,allofthe InvestorsrightsundertheNotesshallbeextinguished(including,withoutlimitation,therights toreceive,asapplicable,anypremium,make-wholeamount,accruedandunpaidinterestor dividendsthereonoranyothersharesofCommonStockwithrespectthereto(whetheruponin connection with a fundamental transaction, event of default or otherwise)). BN 35286522v1  1.3.      TheCompanyandtheInvestorshallexecuteand/ordeliversuchother documentsandagreementsasarecustomaryandreasonablynecessarytoeffectuatethe Exchange. 1.4.      IftheClosinghasnotoccurredonorpriortoDecember31,2018,the Investorshallhavetheright,bydeliveryofwrittennoticetotheCompanytoterminatethis Agreement(suchdate,theTerminationDate).Fromthedatehereofuntiltheearlierof(x)the ClosingDate(asdefinedbelow)and(y)theTerminationDate,theInvestorshallforbearfrom takinganyactionswithrespecttotheNotesnotexplicitlysetforthherein,including,without limitation,conversions,exercises,redemptions,exchangesordeliveryofwrittennoticetothe Company to require the conversion, exercise, redemption or exchange of any of the Notes. 1.5.      It shall be a condition to the obligation of the Investor on the one hand and theCompanyontheotherhand,toconsummatetheExchangecontemplatedhereunderthatthe otherpartysrepresentationsandwarrantiescontainedhereinaretrueandcorrectontheClosing Datewiththesameeffectasthoughmadeonsuchdate,unlesswaivedinwritingbythepartyto whom such representations and warranties are made. 1.6.      At or before the Closing, the Investor shall deliver or cause to be delivered toBuchalterLawFirm,ascounseltotheCompany,(i)theexecutedAgreementand(ii)other items required to effectuate the Exchange.  2. Representations   and   Warranties   of   the   Company.      The   Company   hereby represents and warrants to the Investor that: 2.1.      Concerning the Debenture.     ExceptaslistedonSchedule2.1,thereare nopreemptiverightsofanypersonorentity,rightsoffirstrefusal,participationrights,orother rights to acquire the Debenture. 2.2.      Organization,GoodStandingandQualification.     TheCompanyisa corporationdulyorganized,validlyexistingandingoodstandingunderthelawsoftheStateof Nevada.   TheCompanyisdulyqualifiedtotransactbusinessandisingoodstandingineach jurisdictioninwhichthefailuretosoqualifywouldhaveaMaterialAdverseEffect(asdefined below)onitsbusinessorproperties.AsusedinthisAgreement,MaterialAdverseEffect means  any  material  adverse  effect  on  the  business,  properties,  assets,  liabilities,  operations, resultsofoperations,condition(financialorotherwise)orprospectsoftheCompanyandits Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby orontheExchange(asdefinedbelow)orbytheagreementsandinstrumentstobeenteredinto (or  entered  into)  in  connection  herewith  or  therewith,  or  on  the  authority  or  ability  of  the Company to perform its obligations under this Agreement or the Exchange. 2.3.      Authorization.AllcorporateactiononthepartoftheCompany,its officers, directors and stockholders necessary for the authorization, execution and delivery of this AgreementandtheperformanceofallobligationsoftheCompanyhereunderandthereunder, andtheauthorizationoftheExchange,theissuance(andreservationforissuance)ofthe Debenture have been taken on or prior to the date hereof.  BN 35286522v1 2  2.4.      ValidIssuanceoftheDebenture.     TheDebenturewhenissuedand delivered in accordance with the terms of this Agreement, for the consideration expressed herein, andtheCommonStockwhenissuedinaccordancewiththetermsoftheDebenture,forthe considerationexpressedtherein,willbedulyandvalidlyissued,fullypaidandnon-assessable. UponconversionoftheDebenture,theCommonStockshallbefreelytradableandmaybesold underRule144subjecttotheCompanyhavingfiledallapplicableForm10-Qsandtherequired Form10-K.TheCompanyagreestotakeallactions,including,withoutlimitation,theissuance byitslegalcounselofanynecessarylegalopinions,necessarytoissueunrestrictedCommon StockpursuanttoSection3(a)(9)oftheSecuritiesActandRule144thereunderinconnection withwhichCommonStockissueduponconversionoftheDebentureissuedinexchangeforthe Debenture,theCommonStockwillbefreelytradablewithoutrestrictionandnotcontainingany restrictivelegendwithouttheneedforanyactionbytheInvestorotherthanasrequiredbyRule 144(i)andexecutionoftheapplicablerepresentationletters.Within60daysoftheClosing,the Companyshallhavereservedfromitsdulyauthorizedcapitalstocknotlessthan700%ofthe maximum number of shares of Common Stock issuable upon conversion of the Debenture. 2.5.      ComplianceWithLaws.   TheCompanyhasnotviolatedanylaworany governmentalregulationorrequirementwhichviolationhashadorwouldreasonablybe expectedtohaveaMaterialAdverseEffect,andtheCompanyhasnotreceivedwrittennoticeof any such violation. 2.6.      Consents;  Waivers.    No  consent,  waiver,  approval  or  authority  of  any nature,orotherformalaction,byanyPerson,notalreadyobtained,isrequiredinconnection withtheexecutionanddeliveryofthisAgreementbytheCompanyortheconsummationbythe Company of the transactions provided for herein and therein. 2.7.      AcknowledgmentRegardingInvestorsPurchaseofDebenture.     The CompanyacknowledgesandagreesthattheInvestorisactingsolelyinthecapacityofarms length purchaser with respect to this Agreement and Exchange and the transactions contemplated herebyandtherebyandthattheInvestorisnot(i)anofficerordirectoroftheCompany,(ii)an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), or (iii) to  the  knowledge  of  the  Company,  a  beneficial  owner  of  10%  or  more  of  the  shares  of CommonStock(asdefinedforpurposesofRule13d-3undertheSecuritiesExchangeActof 1934(the Exchange Act).  The Company further acknowledges that the Investor is not acting as afinancialadvisororfiduciaryoftheCompany(orinanysimilarcapacity)withrespecttothe Exchangeandthetransactionscontemplatedherebyandthereby,andanyadvicegivenbythe InvestororanyofitsrepresentativesoragentsinconnectionwiththeExchangeandthe transactions contemplated hereby and thereby is merely incidental to the Investors acceptance of theDebenture.TheCompanyfurtherrepresentstotheInvestorthattheCompanysdecisionto enterintotheExchangehasbeenbasedsolelyontheindependentevaluationbytheCompany and its representatives. 2.8.      AbsenceofLitigation.TotheknowledgeoftheCompany,thereisno action,suit,proceeding,inquiryorinvestigationbeforeorbyanycourt,publicboard, governmentagency,self-regulatoryorganizationorbodypendingor,totheknowledgeofthe Company,  threatened  against  or  affecting  the  Company,  the  Common  Stock,  the  Notes,  the  BN 35286522v1 3  DebentureoranyoftheCompanysofficersordirectorsintheircapacitiesassuch,otherthan what is disclosed in the Companys public filings. 2.9.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validlyauthorized,executedanddeliveredonbehalfoftheCompanyandshallconstitutethe legal,validandbindingobligationsoftheCompanyenforceableagainsttheCompanyin accordancewiththeirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneral principlesofequityortoapplicablebankruptcy,insolvency,reorganization,moratorium, liquidationandothersimilarlawsrelatingto,oraffectinggenerally,theenforcementof applicable  creditors  rights  and  remedies.    The  execution,  delivery  and  performance  by  the CompanyofthisAgreementandtheconsummationbytheCompanyofthetransactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents oftheCompanyor(ii)conflictwith,orconstituteadefault(oraneventwhichwithnoticeor lapseoftimeorbothwouldbecomeadefault)under,orgivetoothersanyrightsoftermination, amendment,accelerationorcancellationof,anyagreement,indentureorinstrumenttowhichthe Company  is  a  party  or  by  which  it  is  bound,  or  (iii)  result  in  a  violation  of  any  law,  rule, regulation,order,judgmentordecree(includingfederalandstatesecuritiesorblueskylaws) applicabletotheCompany,exceptinthecaseofclause(ii)above,forsuchconflicts,defaultsor rightswhichwouldnot,individuallyorintheaggregate,reasonablybeexpectedtoresultina Material Adverse Effect. 2.10.    Authorized   Capital.   Schedule   2.10   sets   forth   all   capital   stock   and derivativesecuritiesoftheCompanythatareauthorizedforissuanceandthatareissuedand outstanding.AllissuedandoutstandingsharesofCommonStockhavebeendulyauthorizedand validlyissuedandarefullypaidandnonassessable.TheCompanyhassufficientauthorizedand unissuedsharesofCommonStockasmaybenecessarytoeffecttheissuanceoftheshares issuable  upon  conversion  of  the  Debenture  (the  Shares),  assuming  the  prior  issuance  and exercise,exchangeorconversion,asthecasemaybe,ofallderivativesecuritiesauthorized,as indicated in Schedule 2.10, (subject to a 60 day grace from Closing). 2.11.    Disclosure.   TheCompanyconfirmsthatneitheritnoranyotherperson actingonitsbehalfhasprovidedtheInvestororitsagentsorcounselwithanyinformationthat constitutesorcouldreasonablybeexpectedtoconstitutematerial,nonpublicinformation.   The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 2.12.     Except as listed on Schedule 2.12 hereto, the Company does not have any indebtednessotherthanPermittedLiens.PermittedLiensshallhavethesamemeaningasin the Debenture.  3. RepresentationsandWarrantiesoftheInvestor.TheInvestorherebyrepresents, warrants and covenants that: 3.1.      Authorization.TheInvestorhasfull powerandauthoritytoenterintothis Agreement,   to   perform   its   obligations   hereunder   and   to   consummate   the   transactions contemplatedherebyandhastakenallactionnecessarytoauthorizetheexecutionanddelivery  BN 35286522v1 4  ofthisAgreement,theperformanceofitsobligationshereunderandtheconsummationofthe transactions contemplated hereby. 3.2.      AccreditedInvestorStatus;InvestmentExperience.TheInvestorisan accreditedinvestorasthattermisdefinedinRule501(a)ofRegulationD.TheInvestorcan beartheeconomicriskofitsinvestmentintheDebenture,andhassuchknowledgeand experienceinfinancialandbusinessmattersthatitiscapableofevaluatingthemeritsandrisks of an investment in the Debenture. 3.3.      No Governmental Review.  The Investor understands that no United States federalorstateagencyoranyothergovernmentorgovernmentalagencyhaspassedonormade any  recommendation  or  endorsement  of  the  Debenture  or  the  fairness  or  suitability  of  the investmentintheDebenturenorhavesuchauthoritiespasseduponorendorsedthemeritsofthe offering of the Debenture 3.4.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, validandbindingobligationsoftheInvestorenforceableagainsttheInvestorinaccordancewith theirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneralprinciplesof equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similarlawsrelatingto,oraffectinggenerally,theenforcementofapplicablecreditorsrights and remedies. 3.5.      Ownership of Securities.  The Investor owns and holds, beneficially and of record,theentireright,title,andinterestinandtotheNotesfreeandclearofallrightsandliens (other than pledges orsecurityinterests(x) arisingby operation of applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with its primebrokerageagreementwithsuchbroker).TheInvestorhasfullpowerandauthorityto transferanddisposeoftheNotestotheCompanyfreeandclearofanyrightorlien.Otherthan the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal, orotherrightofanyPersontoacquirealloranypartoftheNotesoranysharesofCommon Stock issuable upon conversion of the Debenture.  4. Additional Covenants 4.1.      Disclosure.TheCompanyshall,onorbefore8:30a.m.,NewYorkNew York time, within four business days after the date of this Agreement, file with the Securities and Exchange  Commission  a  Current  Report  on  Form  8-K  disclosing  all  material  terms  of  the transactions contemplated hereby and attaching the form of this Agreement and the Debenture as exhibits thereto (collectively with all exhibits attached thereto, the 8-K Filing).From and after theissuanceofthe8-KFilingtheInvestorshallnotbeinpossessionofanymaterial,nonpublic informationreceivedfromtheCompanyoranyofitsSubsidiariesoranyoftheirrespective officers,directors,employees,affiliatesoragents,thatisnotdisclosedinthe8-KFiling.   The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, providetheInvestorwithanymaterial,nonpublicinformationregardingtheCompanyfromand  BN 35286522v1 5  afterthefilingofthe8-KFilingwithouttheexpresswrittenconsentoftheInvestor.Tothe extentthattheCompanydeliversanymaterial,non-publicinformationtotheInvestorwithout theInvestorsexpresspriorwrittenconsent,theCompanyherebycovenantsandagreesthatthe InvestorshallnothaveanydutyofconfidentialitytotheCompany,anyofitssubsidiariesorany oftheirrespectiveofficers,directors,employees,affiliatesoragentwithrespectto,oradutyto theCompany,anyofitssubsidiariesoranyoftheirrespectiveofficers,directors,employees, affiliatesoragentornottotradeonthebasisof,suchmaterial,non-publicinformation.   The CompanyshallnotdisclosethenameoftheInvestorinanyfiling,announcement,releaseor otherwise, unless such disclosure is required by law or regulation.  In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similarobligationsunderanyagreement,whetherwrittenororal,betweentheCompany,anyof itssubsidiariesoranyoftheirrespectiveofficers,directors,affiliates,employeesoragents,on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be of nofurtherforceoreffect.TheCompanyunderstandsandconfirmsthattheInvestorwillrelyon the foregoing representations in effecting transactions in securities of the Company. 4.2.      HoldingPeriod.ForthepurposesofSection3(a)(9)andRule144ofthe SecuritiesAct,theCompanyacknowledgesthat(i)theholdingperiodoftheNotesmaybe tackedontotheholdingperiodoftheDebentureaslongasnopaymentismadeinconnection with any conversion, and (ii) the holding period of the Debenture may be tacked onto the holding period of the Shares, and the Company agrees not to take a position contrary to this Section 4.2. 4.3.      Blue Sky.The Company shall make all filings and reports relating to the ExchangerequiredbyRegulationDundertheSecuritiesActandunderapplicablesecuritiesor Blue Sky laws of the states of the United States following the date hereof. 4.4.      Fees and Expenses.  Except as otherwise set forth above, each party to this Agreement  shall  pay  the  fees  and  expenses  of  its  advisers,  counsel,  accountants  and  other experts,  if  any,  and  all  other  expenses  incurred  by  such  party  incident  to  the  negotiation, preparation, execution, delivery and performance of this Agreement.  5. Miscellaneous 5.1.      SuccessorsandAssigns.   Exceptasotherwiseprovidedherein,theterms andconditionsofthisAgreementshallinuretothebenefitofandbebindingupontheparties heretoandtherespectivesuccessorsandassignsoftheparties.NothinginthisAgreement, expressorimplied,isintendedtoconferuponanyparty,otherthanthepartiesheretoortheir respectivesuccessorsandassigns,anyrights,remedies,obligationsorliabilitiesunderorby reason of this Agreement, except as expressly provided in this Agreement. 5.2.      Governing  Law;  Exclusive  Jurisdiction.    All  questions  concerning  the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internallawsoftheStateofNewYork,withoutgivingeffecttoanychoiceoflaworconflictof lawprovisionorrule(whetheroftheStateofNewYorkoranyotherjurisdictions)thatwould causetheapplicationofthelawsofanyjurisdictionsotherthantheStateofNewYork.   Each  BN 35286522v1 6  party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting inNewYorkCounty,NewYork,fortheadjudicationofanydisputehereunderorinconnection herewithorwithanytransactioncontemplatedherebyordiscussedherein,andhereby irrevocablywaives,andagreesnottoassertinanysuit,actionorproceeding,anyclaimthatitis not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought  in  an  inconvenient  forumor  that  thevenue  of  such  suit,  action  or  proceeding  is improper. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 5.3.      Notices.    All  notices,  offers,  acceptance  and  any  other  acts  under  this Agreement(exceptpayment)shallbeinwriting,andshallbesufficientlygivenifdeliveredto theaddresseesinperson,byFedExorsimilarovernightnextbusinessdaydelivery,orbyemail followed by overnight next business day delivery, to the address as provided for on the signature page to this agreement. 5.4.      AmendmentsandWaivers.AnytermofthisAgreementmaybeamended andtheobservanceofanytermofthisAgreementmaybewaived(eithergenerallyorina particularinstanceandeitherretroactivelyorprospectively),onlywiththewrittenconsentofthe Company and the Investor. 5.5.      Severability.IfoneormoreprovisionsofthisAgreementareheldtobe unenforceableunderapplicablelaw,suchprovisionshallbeexcludedfromthisAgreementand the balance of the Agreement shall be interpreted as if such provision were so excluded and shall beenforceableinaccordancewithitstermssolongasthisAgreementassomodifiedcontinues toexpress,withoutmaterialchange,theoriginalintentionsofthepartiesastothesubjectmatter hereofandtheprohibitednature,invalidityorunenforceabilityoftheprovision(s)inquestion doesnotsubstantiallyimpairtherespectiveexpectationsorreciprocalobligationsoftheparties orthepracticalrealizationofthebenefitsthatwouldotherwisebeconferredupontheparties. Thepartieswillendeavoringoodfaithnegotiationstoreplacetheprohibited,invalidor unenforceable  provision(s)  with  a  valid  provision(s),  the  effect  of  which  comes  as  close  as possible to that of the prohibited, invalid or unenforceable provision(s). 5.6.      Counterparts.      This   Agreement   may   be   executed   in   two   or   more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 5.7.      Survival.Therepresentations,warrantiesandcovenantsoftheCompany and the Investor contained herein shall survive the Closing and delivery of the Debenture [SIGNATURES ON THE FOLLOWING PAGE]  BN 35286522v1 7  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. COMPANY: PARALLAX HEALTH SCIENCES, INC. By:   ______________________________________ Name:  Paul Arena Title:    Chief Executive Officer BN 35286522v1  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. INVESTOR: Cavalry Fund I LP By: Cavalry Fund I Management LLC Its: General Partner By: ________________________________ Name: Thomas P. Walsh Title: Manager Address for Notices: ________________________  ________________________  ________________________ Email: ___________________  SSN#: ___________________    BN 35286522v1  EXHIBIT A Debenture [See attached] BN 35286522v1  Schedule I  Note Issuance Date Amount Amount of Debenture  Convertible NoteJune 14, 2018 $250,000.00 $313,036.86 M:\10401\Private Placements\Parallax\Exchange Agreement 11-27-18.docx/csb BN 35286522v1  Schedule 2.12  Lien Holder Issuance Date Principal Amount of Interest/Penalties  Amount As of 9-30-18  Shahla Melamed* August 14, 2015     $20,550,000 $2,278,281  Internal Revenue Service* Pending $     658,921 $   298,908  State of California, EDD* January 29, 2018    $     125,399 $     65,583 *Related to RoxSan Pharmacy, Inc. subsidiary BN 35286522v1  EXCHANGE AGREEMENT THIS  EXCHANGE  AGREEMENT  (the  Agreement)  is  made  as  of  the  31st  day  of DecemberandeffectiveNovember14,2018,byandbetween,ParallaxHealthSciences,Inc.,a Nevadacorporation,(theCompany)andDiamondRock,LLC,aNewYorklimitedliability company (the Investor). WHEREAS, the Investor has previously acquired various securities from the Company in theformofconvertiblenoteswithvariousdatesofissuanceassetforthonScheduleI(the Notes). WHEREAS,  the  Company  has  authorized  a  new  series  of  convertible  debenture  due February28,2019,intheformofExhibitAhereto,whichwillbeconvertibleintosharesofthe Companys Common Stock, par value $0.001. WHEREAS,subjecttothesatisfactionoftheconditionssetforthherein,theCompany andtheInvestordesiretoenterintoatransactionwhereintheCompanyshallissuetheInvestor the debenture intheamountof$150,194.92 (theDebenture) in exchange for each of the Notes as set forth on Schedule I (the Exchange). NOW,THEREFORE,forgoodandvaluableconsideration,thereceiptandsufficiencyof which are hereby acknowledged, the parties agree as follows:  1. Exchange.  The closing of the Exchange (the Closing) will occur on or before December 31, 2018 (or such later date as the parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date, the Closing Date). On the Closing Date, subject to the terms and conditions of this Agreement, the Investor shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the Securities Act), exchange the Notes for the Debenture. At the Closing, the following transactions shall occur (such transactions in this Section 1, the Exchange): 1.1.      OntheClosingDate,theCompanyshallissuetheDebenturetothe Investor.  Promptly  after  the  Closing  Date,  the  Company  shall  deliver  an  executed  original DebenturetotheInvestor.OntheClosingDate,theInvestorshallbedeemedforallcorporate purposestohavebecometheholderofrecordoftheDebentureandshallhavetherightto convert  the  Debenture,  irrespective  of  the  date  the  Company  delivers  the  Debenture  to  the Investor. 1.2.      UponreceiptoftheDebentureinaccordancewithSection1.1,allofthe InvestorsrightsundertheNotesshallbeextinguished(including,withoutlimitation,therights toreceive,asapplicable,anypremium,make-wholeamount,accruedandunpaidinterestor dividendsthereonoranyothersharesofCommonStockwithrespectthereto(whetheruponin connection with a fundamental transaction, event of default or otherwise)). BN 35285973v1  1.3.      TheCompanyandtheInvestorshallexecuteand/ordeliversuchother documentsandagreementsasarecustomaryandreasonablynecessarytoeffectuatethe Exchange. 1.4.      IftheClosinghasnotoccurredonorpriortoDecember31,2018,the Investorshallhavetheright,bydeliveryofwrittennoticetotheCompanytoterminatethis Agreement(suchdate,theTerminationDate).Fromthedatehereofuntiltheearlierof(x)the ClosingDate(asdefinedbelow)and(y)theTerminationDate,theInvestorshallforbearfrom takinganyactionswithrespecttotheNotesnotexplicitlysetforthherein,including,without limitation,conversions,exercises,redemptions,exchangesordeliveryofwrittennoticetothe Company to require the conversion, exercise, redemption or exchange of any of the Notes. 1.5.      It shall be a condition to the obligation of the Investor on the one hand and theCompanyontheotherhand,toconsummatetheExchangecontemplatedhereunderthatthe otherpartysrepresentationsandwarrantiescontainedhereinaretrueandcorrectontheClosing Datewiththesameeffectasthoughmadeonsuchdate,unlesswaivedinwritingbythepartyto whom such representations and warranties are made. 1.6.      At or before the Closing, the Investor shall deliver or cause to be delivered toBuchalterLawFirm,ascounseltotheCompany,(i)theexecutedAgreementand(ii)other items required to effectuate the Exchange.  2. Representations   and   Warranties   of   the   Company.      The   Company   hereby represents and warrants to the Investor that: 2.1.      Concerning the Debenture.     ExceptaslistedonSchedule2.1,thereare nopreemptiverightsofanypersonorentity,rightsoffirstrefusal,participationrights,orother rights to acquire the Debenture. 2.2.      Organization,GoodStandingandQualification.     TheCompanyisa corporationdulyorganized,validlyexistingandingoodstandingunderthelawsoftheStateof Nevada.   TheCompanyisdulyqualifiedtotransactbusinessandisingoodstandingineach jurisdictioninwhichthefailuretosoqualifywouldhaveaMaterialAdverseEffect(asdefined below)onitsbusinessorproperties.AsusedinthisAgreement,MaterialAdverseEffect means  any  material  adverse  effect  on  the  business,  properties,  assets,  liabilities,  operations, resultsofoperations,condition(financialorotherwise)orprospectsoftheCompanyandits Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby orontheExchange(asdefinedbelow)orbytheagreementsandinstrumentstobeenteredinto (or  entered  into)  in  connection  herewith  or  therewith,  or  on  the  authority  or  ability  of  the Company to perform its obligations under this Agreement or the Exchange. 2.3.      Authorization.AllcorporateactiononthepartoftheCompany,its officers, directors and stockholders necessary for the authorization, execution and delivery of this AgreementandtheperformanceofallobligationsoftheCompanyhereunderandthereunder, andtheauthorizationoftheExchange,theissuance(andreservationforissuance)ofthe Debenture have been taken on or prior to the date hereof.  BN 35285973v1 2  2.4.      ValidIssuanceoftheDebenture.     TheDebenturewhenissuedand delivered in accordance with the terms of this Agreement, for the consideration expressed herein, andtheCommonStockwhenissuedinaccordancewiththetermsoftheDebenture,forthe considerationexpressedtherein,willbedulyandvalidlyissued,fullypaidandnon-assessable. UponconversionoftheDebenture,theCommonStockshallbefreelytradableandmaybesold underRule144subjecttotheCompanyhavingfiledallapplicableForm10-Qsandtherequired Form10-K.TheCompanyagreestotakeallactions,including,withoutlimitation,theissuance byitslegalcounselofanynecessarylegalopinions,necessarytoissueunrestrictedCommon StockpursuanttoSection3(a)(9)oftheSecuritiesActandRule144thereunderinconnection withwhichCommonStockissueduponconversionoftheDebentureissuedinexchangeforthe Debenture,theCommonStockwillbefreelytradablewithoutrestrictionandnotcontainingany restrictivelegendwithouttheneedforanyactionbytheInvestorotherthanasrequiredbyRule 144(i)andexecutionoftheapplicablerepresentationletters.Within60daysoftheClosing,the Companyshallhavereservedfromitsdulyauthorizedcapitalstocknotlessthan700%ofthe maximum number of shares of Common Stock issuable upon conversion of the Debenture. 2.5.      ComplianceWithLaws.   TheCompanyhasnotviolatedanylaworany governmentalregulationorrequirementwhichviolationhashadorwouldreasonablybe expectedtohaveaMaterialAdverseEffect,andtheCompanyhasnotreceivedwrittennoticeof any such violation. 2.6.      Consents;  Waivers.    No  consent,  waiver,  approval  or  authority  of  any nature,orotherformalaction,byanyPerson,notalreadyobtained,isrequiredinconnection withtheexecutionanddeliveryofthisAgreementbytheCompanyortheconsummationbythe Company of the transactions provided for herein and therein. 2.7.      AcknowledgmentRegardingInvestorsPurchaseofDebenture.     The CompanyacknowledgesandagreesthattheInvestorisactingsolelyinthecapacityofarms length purchaser with respect to this Agreement and Exchange and the transactions contemplated herebyandtherebyandthattheInvestorisnot(i)anofficerordirectoroftheCompany,(ii)an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), or (iii) to  the  knowledge  of  the  Company,  a  beneficial  owner  of  10%  or  more  of  the  shares  of CommonStock(asdefinedforpurposesofRule13d-3undertheSecuritiesExchangeActof 1934(the Exchange Act).  The Company further acknowledges that the Investor is not acting as afinancialadvisororfiduciaryoftheCompany(orinanysimilarcapacity)withrespecttothe Exchangeandthetransactionscontemplatedherebyandthereby,andanyadvicegivenbythe InvestororanyofitsrepresentativesoragentsinconnectionwiththeExchangeandthe transactions contemplated hereby and thereby is merely incidental to the Investors acceptance of theDebenture.TheCompanyfurtherrepresentstotheInvestorthattheCompanysdecisionto enterintotheExchangehasbeenbasedsolelyontheindependentevaluationbytheCompany and its representatives. 2.8.      AbsenceofLitigation.TotheknowledgeoftheCompany,thereisno action,suit,proceeding,inquiryorinvestigationbeforeorbyanycourt,publicboard, governmentagency,self-regulatoryorganizationorbodypendingor,totheknowledgeofthe Company,  threatened  against  or  affecting  the  Company,  the  Common  Stock,  the  Notes,  the  BN 35285973v1 3  DebentureoranyoftheCompanysofficersordirectorsintheircapacitiesassuch,otherthan what is disclosed in the Companys public filings. 2.9.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validlyauthorized,executedanddeliveredonbehalfoftheCompanyandshallconstitutethe legal,validandbindingobligationsoftheCompanyenforceableagainsttheCompanyin accordancewiththeirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneral principlesofequityortoapplicablebankruptcy,insolvency,reorganization,moratorium, liquidationandothersimilarlawsrelatingto,oraffectinggenerally,theenforcementof applicable  creditors  rights  and  remedies.    The  execution,  delivery  and  performance  by  the CompanyofthisAgreementandtheconsummationbytheCompanyofthetransactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents oftheCompanyor(ii)conflictwith,orconstituteadefault(oraneventwhichwithnoticeor lapseoftimeorbothwouldbecomeadefault)under,orgivetoothersanyrightsoftermination, amendment,accelerationorcancellationof,anyagreement,indentureorinstrumenttowhichthe Company  is  a  party  or  by  which  it  is  bound,  or  (iii)  result  in  a  violation  of  any  law,  rule, regulation,order,judgmentordecree(includingfederalandstatesecuritiesorblueskylaws) applicabletotheCompany,exceptinthecaseofclause(ii)above,forsuchconflicts,defaultsor rightswhichwouldnot,individuallyorintheaggregate,reasonablybeexpectedtoresultina Material Adverse Effect. 2.10.    Authorized   Capital.   Schedule   2.10   sets   forth   all   capital   stock   and derivativesecuritiesoftheCompanythatareauthorizedforissuanceandthatareissuedand outstanding.AllissuedandoutstandingsharesofCommonStockhavebeendulyauthorizedand validlyissuedandarefullypaidandnonassessable.TheCompanyhassufficientauthorizedand unissuedsharesofCommonStockasmaybenecessarytoeffecttheissuanceoftheshares issuable  upon  conversion  of  the  Debenture  (the  Shares),  assuming  the  prior  issuance  and exercise,exchangeorconversion,asthecasemaybe,ofallderivativesecuritiesauthorized,as indicated in Schedule 2.10, (subject to a 60 day grace from Closing). 2.11.    Disclosure.   TheCompanyconfirmsthatneitheritnoranyotherperson actingonitsbehalfhasprovidedtheInvestororitsagentsorcounselwithanyinformationthat constitutesorcouldreasonablybeexpectedtoconstitutematerial,nonpublicinformation.   The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 2.12.     Except as listed on Schedule 2.12 hereto, the Company does not have any indebtednessotherthanPermittedLiens.PermittedLiensshallhavethesamemeaningasin the Debenture.  3. RepresentationsandWarrantiesoftheInvestor.TheInvestorherebyrepresents, warrants and covenants that: 3.1.      Authorization.TheInvestorhasfull powerandauthoritytoenterintothis Agreement,   to   perform   its   obligations   hereunder   and   to   consummate   the   transactions contemplatedherebyandhastakenallactionnecessarytoauthorizetheexecutionanddelivery  BN 35285973v1 4  ofthisAgreement,theperformanceofitsobligationshereunderandtheconsummationofthe transactions contemplated hereby. 3.2.      AccreditedInvestorStatus;InvestmentExperience.TheInvestorisan accreditedinvestorasthattermisdefinedinRule501(a)ofRegulationD.TheInvestorcan beartheeconomicriskofitsinvestmentintheDebenture,andhassuchknowledgeand experienceinfinancialandbusinessmattersthatitiscapableofevaluatingthemeritsandrisks of an investment in the Debenture. 3.3.      No Governmental Review.  The Investor understands that no United States federalorstateagencyoranyothergovernmentorgovernmentalagencyhaspassedonormade any  recommendation  or  endorsement  of  the  Debenture  or  the  fairness  or  suitability  of  the investmentintheDebenturenorhavesuchauthoritiespasseduponorendorsedthemeritsofthe offering of the Debenture 3.4.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, validandbindingobligationsoftheInvestorenforceableagainsttheInvestorinaccordancewith theirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneralprinciplesof equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similarlawsrelatingto,oraffectinggenerally,theenforcementofapplicablecreditorsrights and remedies. 3.5.      Ownership of Securities.  The Investor owns and holds, beneficially and of record,theentireright,title,andinterestinandtotheNotesfreeandclearofallrightsandliens (other than pledges orsecurityinterests(x) arisingby operation of applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with its primebrokerageagreementwithsuchbroker).TheInvestorhasfullpowerandauthorityto transferanddisposeoftheNotestotheCompanyfreeandclearofanyrightorlien.Otherthan the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal, orotherrightofanyPersontoacquirealloranypartoftheNotesoranysharesofCommon Stock issuable upon conversion of the Debenture.  4. Additional Covenants 4.1.      Disclosure.TheCompanyshall,onorbefore8:30a.m.,NewYorkNew York time, within four business days after the date of this Agreement, file with the Securities and Exchange  Commission  a  Current  Report  on  Form  8-K  disclosing  all  material  terms  of  the transactions contemplated hereby and attaching the form of this Agreement and the Debenture as exhibits thereto (collectively with all exhibits attached thereto, the 8-K Filing).From and after theissuanceofthe8-KFilingtheInvestorshallnotbeinpossessionofanymaterial,nonpublic informationreceivedfromtheCompanyoranyofitsSubsidiariesoranyoftheirrespective officers,directors,employees,affiliatesoragents,thatisnotdisclosedinthe8-KFiling.   The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, providetheInvestorwithanymaterial,nonpublicinformationregardingtheCompanyfromand  BN 35285973v1 5  afterthefilingofthe8-KFilingwithouttheexpresswrittenconsentoftheInvestor.Tothe extentthattheCompanydeliversanymaterial,non-publicinformationtotheInvestorwithout theInvestorsexpresspriorwrittenconsent,theCompanyherebycovenantsandagreesthatthe InvestorshallnothaveanydutyofconfidentialitytotheCompany,anyofitssubsidiariesorany oftheirrespectiveofficers,directors,employees,affiliatesoragentwithrespectto,oradutyto theCompany,anyofitssubsidiariesoranyoftheirrespectiveofficers,directors,employees, affiliatesoragentornottotradeonthebasisof,suchmaterial,non-publicinformation.   The CompanyshallnotdisclosethenameoftheInvestorinanyfiling,announcement,releaseor otherwise, unless such disclosure is required by law or regulation.  In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similarobligationsunderanyagreement,whetherwrittenororal,betweentheCompany,anyof itssubsidiariesoranyoftheirrespectiveofficers,directors,affiliates,employeesoragents,on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be of nofurtherforceoreffect.TheCompanyunderstandsandconfirmsthattheInvestorwillrelyon the foregoing representations in effecting transactions in securities of the Company. 4.2.      HoldingPeriod.ForthepurposesofSection3(a)(9)andRule144ofthe SecuritiesAct,theCompanyacknowledgesthat(i)theholdingperiodoftheNotesmaybe tackedontotheholdingperiodoftheDebentureaslongasnopaymentismadeinconnection with any conversion, and (ii) the holding period of the Debenture may be tacked onto the holding period of the Shares, and the Company agrees not to take a position contrary to this Section 4.2. 4.3.      Blue Sky.The Company shall make all filings and reports relating to the ExchangerequiredbyRegulationDundertheSecuritiesActandunderapplicablesecuritiesor Blue Sky laws of the states of the United States following the date hereof. 4.4.      Fees and Expenses.  Except as otherwise set forth above, each party to this Agreement  shall  pay  the  fees  and  expenses  of  its  advisers,  counsel,  accountants  and  other experts,  if  any,  and  all  other  expenses  incurred  by  such  party  incident  to  the  negotiation, preparation, execution, delivery and performance of this Agreement.  5. Miscellaneous 5.1.      SuccessorsandAssigns.   Exceptasotherwiseprovidedherein,theterms andconditionsofthisAgreementshallinuretothebenefitofandbebindingupontheparties heretoandtherespectivesuccessorsandassignsoftheparties.NothinginthisAgreement, expressorimplied,isintendedtoconferuponanyparty,otherthanthepartiesheretoortheir respectivesuccessorsandassigns,anyrights,remedies,obligationsorliabilitiesunderorby reason of this Agreement, except as expressly provided in this Agreement. 5.2.      Governing  Law;  Exclusive  Jurisdiction.    All  questions  concerning  the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internallawsoftheStateofNewYork,withoutgivingeffecttoanychoiceoflaworconflictof lawprovisionorrule(whetheroftheStateofNewYorkoranyotherjurisdictions)thatwould causetheapplicationofthelawsofanyjurisdictionsotherthantheStateofNewYork.   Each  BN 35285973v1 6  party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting inNewYorkCounty,NewYork,fortheadjudicationofanydisputehereunderorinconnection herewithorwithanytransactioncontemplatedherebyordiscussedherein,andhereby irrevocablywaives,andagreesnottoassertinanysuit,actionorproceeding,anyclaimthatitis not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought  in  an  inconvenient  forumor  that  thevenue  of  such  suit,  action  or  proceeding  is improper. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 5.3.      Notices.    All  notices,  offers,  acceptance  and  any  other  acts  under  this Agreement(exceptpayment)shallbeinwriting,andshallbesufficientlygivenifdeliveredto theaddresseesinperson,byFedExorsimilarovernightnextbusinessdaydelivery,orbyemail followed by overnight next business day delivery, to the address as provided for on the signature page to this agreement. 5.4.      AmendmentsandWaivers.AnytermofthisAgreementmaybeamended andtheobservanceofanytermofthisAgreementmaybewaived(eithergenerallyorina particularinstanceandeitherretroactivelyorprospectively),onlywiththewrittenconsentofthe Company and the Investor. 5.5.      Severability.IfoneormoreprovisionsofthisAgreementareheldtobe unenforceableunderapplicablelaw,suchprovisionshallbeexcludedfromthisAgreementand the balance of the Agreement shall be interpreted as if such provision were so excluded and shall beenforceableinaccordancewithitstermssolongasthisAgreementassomodifiedcontinues toexpress,withoutmaterialchange,theoriginalintentionsofthepartiesastothesubjectmatter hereofandtheprohibitednature,invalidityorunenforceabilityoftheprovision(s)inquestion doesnotsubstantiallyimpairtherespectiveexpectationsorreciprocalobligationsoftheparties orthepracticalrealizationofthebenefitsthatwouldotherwisebeconferredupontheparties. Thepartieswillendeavoringoodfaithnegotiationstoreplacetheprohibited,invalidor unenforceable  provision(s)  with  a  valid  provision(s),  the  effect  of  which  comes  as  close  as possible to that of the prohibited, invalid or unenforceable provision(s). 5.6.      Counterparts.      This   Agreement   may   be   executed   in   two   or   more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 5.7.      Survival.Therepresentations,warrantiesandcovenantsoftheCompany and the Investor contained herein shall survive the Closing and delivery of the Debenture [SIGNATURES ON THE FOLLOWING PAGE]  BN 35285973v1 7  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. COMPANY: PARALLAX HEALTH SCIENCES, INC. By:   ______________________________________ Name:  Paul Arena Title:    Chief Executive Officer BN 35285973v1


[ex1041exchangeagreements1.jpg]


EXHIBIT A Debenture [See attached] BN 35285973v1  Schedule I  Note Issuance Date Amount Amount of Debenture  Convertible Note      May 1, 2018 $50,000.00 $63,330.25  Convertible Note      May 29, 2018 $50,000.00 $62,869.98  Convertible Note      June 14, 2018 $16,667.00 $20,869.68 BN 35285973v1  Schedule 2.12  Lien Holder Issuance Date Principal Amount of Interest/Penalties  Amount As of 9-30-18  Shahla Melamed* August 14, 2015     $20,550,000 $2,278,281  Internal Revenue Service* Pending $     658,921 $   298,908  State of California, EDD* January 29, 2018    $     125,399 $     65,583 *Related to RoxSan Pharmacy, Inc. subsidiary BN 35285973v1  EXCHANGE AGREEMENT THIS  EXCHANGE  AGREEMENT  (the  Agreement)  is  made  as  of  the  31st  day  of DecemberandeffectiveNovember14,2018,byandbetween,ParallaxHealthSciences,Inc.,a Nevada corporation, (the Company) andTHE CORBRAN, LLC a New York limited liability company (the Investor). WHEREAS, the Investor has previously acquired various securities from the Company in theformofconvertiblenoteswithvariousdatesofissuanceassetforthonScheduleI(the Notes). WHEREAS,  the  Company  has  authorized  a  new  series  of  convertible  debenture  due February28,2019,intheformofExhibitAhereto,whichwillbeconvertibleintosharesofthe Companys Common Stock, par value $0.001. WHEREAS,subjecttothesatisfactionoftheconditionssetforthherein,theCompany andtheInvestordesiretoenterintoatransactionwhereintheCompanyshallissuetheInvestor thedebentureintheamountof$73,878.61(theDebenture)inexchangeforeachoftheNotes as set forth on Schedule I (the Exchange). NOW,THEREFORE,forgoodandvaluableconsideration,thereceiptandsufficiencyof which are hereby acknowledged, the parties agree as follows:  1. Exchange.  The closing of the Exchange (the Closing) will occur on or before December 31, 2018 (or such later date as the parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date, the Closing Date). On the Closing Date, subject to the terms and conditions of this Agreement, the Investor shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the Securities Act), exchange the Notes for the Debenture. At the Closing, the following transactions shall occur (such transactions in this Section 1, the Exchange): 1.1.      OntheClosingDate,theCompanyshallissuetheDebenturetothe Investor.  Promptly  after  the  Closing  Date,  the  Company  shall  deliver  an  executed  original DebenturetotheInvestor.OntheClosingDate,theInvestorshallbedeemedforallcorporate purposestohavebecometheholderofrecordoftheDebentureandshallhavetherightto convert  the  Debenture,  irrespective  of  the  date  the  Company  delivers  the  Debenture  to  the Investor. 1.2.      UponreceiptoftheDebentureinaccordancewithSection1.1,allofthe InvestorsrightsundertheNotesshallbeextinguished(including,withoutlimitation,therights toreceive,asapplicable,anypremium,make-wholeamount,accruedandunpaidinterestor dividendsthereonoranyothersharesofCommonStockwithrespectthereto(whetheruponin connection with a fundamental transaction, event of default or otherwise)). BN 35285827v1  1.3.      TheCompanyandtheInvestorshallexecuteand/ordeliversuchother documentsandagreementsasarecustomaryandreasonablynecessarytoeffectuatethe Exchange. 1.4.      IftheClosinghasnotoccurredonorpriortoDecember31,2018,the Investorshallhavetheright,bydeliveryofwrittennoticetotheCompanytoterminatethis Agreement(suchdate,theTerminationDate).Fromthedatehereofuntiltheearlierof(x)the ClosingDate(asdefinedbelow)and(y)theTerminationDate,theInvestorshallforbearfrom takinganyactionswithrespecttotheNotesnotexplicitlysetforthherein,including,without limitation,conversions,exercises,redemptions,exchangesordeliveryofwrittennoticetothe Company to require the conversion, exercise, redemption or exchange of any of the Notes. 1.5.      It shall be a condition to the obligation of the Investor on the one hand and theCompanyontheotherhand,toconsummatetheExchangecontemplatedhereunderthatthe otherpartysrepresentationsandwarrantiescontainedhereinaretrueandcorrectontheClosing Datewiththesameeffectasthoughmadeonsuchdate,unlesswaivedinwritingbythepartyto whom such representations and warranties are made. 1.6.      At or before the Closing, the Investor shall deliver or cause to be delivered toBuchalterLawFirm,ascounseltotheCompany,(i)theexecutedAgreementand(ii)other items required to effectuate the Exchange.  2. Representations   and   Warranties   of   the   Company.      The   Company   hereby represents and warrants to the Investor that: 2.1.      Concerning the Debenture.     ExceptaslistedonSchedule2.1,thereare nopreemptiverightsofanypersonorentity,rightsoffirstrefusal,participationrights,orother rights to acquire the Debenture. 2.2.      Organization,GoodStandingandQualification.     TheCompanyisa corporationdulyorganized,validlyexistingandingoodstandingunderthelawsoftheStateof Nevada.   TheCompanyisdulyqualifiedtotransactbusinessandisingoodstandingineach jurisdictioninwhichthefailuretosoqualifywouldhaveaMaterialAdverseEffect(asdefined below)onitsbusinessorproperties.AsusedinthisAgreement,MaterialAdverseEffect means  any  material  adverse  effect  on  the  business,  properties,  assets,  liabilities,  operations, resultsofoperations,condition(financialorotherwise)orprospectsoftheCompanyandits Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby orontheExchange(asdefinedbelow)orbytheagreementsandinstrumentstobeenteredinto (or  entered  into)  in  connection  herewith  or  therewith,  or  on  the  authority  or  ability  of  the Company to perform its obligations under this Agreement or the Exchange. 2.3.      Authorization.AllcorporateactiononthepartoftheCompany,its officers, directors and stockholders necessary for the authorization, execution and delivery of this AgreementandtheperformanceofallobligationsoftheCompanyhereunderandthereunder, andtheauthorizationoftheExchange,theissuance(andreservationforissuance)ofthe Debenture have been taken on or prior to the date hereof.  BN 35285827v1 2  2.4.      ValidIssuanceoftheDebenture.     TheDebenturewhenissuedand delivered in accordance with the terms of this Agreement, for the consideration expressed herein, andtheCommonStockwhenissuedinaccordancewiththetermsoftheDebenture,forthe considerationexpressedtherein,willbedulyandvalidlyissued,fullypaidandnon-assessable. UponconversionoftheDebenture,theCommonStockshallbefreelytradableandmaybesold underRule144subjecttotheCompanyhavingfiledallapplicableForm10-Qsandtherequired Form10-K.TheCompanyagreestotakeallactions,including,withoutlimitation,theissuance byitslegalcounselofanynecessarylegalopinions,necessarytoissueunrestrictedCommon StockpursuanttoSection3(a)(9)oftheSecuritiesActandRule144thereunderinconnection withwhichCommonStockissueduponconversionoftheDebentureissuedinexchangeforthe Debenture,theCommonStockwillbefreelytradablewithoutrestrictionandnotcontainingany restrictivelegendwithouttheneedforanyactionbytheInvestorotherthanasrequiredbyRule 144(i)andexecutionoftheapplicablerepresentationletters.Within60daysoftheClosing,the Companyshallhavereservedfromitsdulyauthorizedcapitalstocknotlessthan700%ofthe maximum number of shares of Common Stock issuable upon conversion of the Debenture. 2.5.      ComplianceWithLaws.   TheCompanyhasnotviolatedanylaworany governmentalregulationorrequirementwhichviolationhashadorwouldreasonablybe expectedtohaveaMaterialAdverseEffect,andtheCompanyhasnotreceivedwrittennoticeof any such violation. 2.6.      Consents;  Waivers.    No  consent,  waiver,  approval  or  authority  of  any nature,orotherformalaction,byanyPerson,notalreadyobtained,isrequiredinconnection withtheexecutionanddeliveryofthisAgreementbytheCompanyortheconsummationbythe Company of the transactions provided for herein and therein. 2.7.      AcknowledgmentRegardingInvestorsPurchaseofDebenture.     The CompanyacknowledgesandagreesthattheInvestorisactingsolelyinthecapacityofarms length purchaser with respect to this Agreement and Exchange and the transactions contemplated herebyandtherebyandthattheInvestorisnot(i)anofficerordirectoroftheCompany,(ii)an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), or (iii) to  the  knowledge  of  the  Company,  a  beneficial  owner  of  10%  or  more  of  the  shares  of CommonStock(asdefinedforpurposesofRule13d-3undertheSecuritiesExchangeActof 1934(the Exchange Act).  The Company further acknowledges that the Investor is not acting as afinancialadvisororfiduciaryoftheCompany(orinanysimilarcapacity)withrespecttothe Exchangeandthetransactionscontemplatedherebyandthereby,andanyadvicegivenbythe InvestororanyofitsrepresentativesoragentsinconnectionwiththeExchangeandthe transactions contemplated hereby and thereby is merely incidental to the Investors acceptance of theDebenture.TheCompanyfurtherrepresentstotheInvestorthattheCompanysdecisionto enterintotheExchangehasbeenbasedsolelyontheindependentevaluationbytheCompany and its representatives. 2.8.      AbsenceofLitigation.TotheknowledgeoftheCompany,thereisno action,suit,proceeding,inquiryorinvestigationbeforeorbyanycourt,publicboard, governmentagency,self-regulatoryorganizationorbodypendingor,totheknowledgeofthe Company,  threatened  against  or  affecting  the  Company,  the  Common  Stock,  the  Notes,  the  BN 35285827v1 3  DebentureoranyoftheCompanysofficersordirectorsintheircapacitiesassuch,otherthan what is disclosed in the Companys public filings. 2.9.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validlyauthorized,executedanddeliveredonbehalfoftheCompanyandshallconstitutethe legal,validandbindingobligationsoftheCompanyenforceableagainsttheCompanyin accordancewiththeirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneral principlesofequityortoapplicablebankruptcy,insolvency,reorganization,moratorium, liquidationandothersimilarlawsrelatingto,oraffectinggenerally,theenforcementof applicable  creditors  rights  and  remedies.    The  execution,  delivery  and  performance  by  the CompanyofthisAgreementandtheconsummationbytheCompanyofthetransactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents oftheCompanyor(ii)conflictwith,orconstituteadefault(oraneventwhichwithnoticeor lapseoftimeorbothwouldbecomeadefault)under,orgivetoothersanyrightsoftermination, amendment,accelerationorcancellationof,anyagreement,indentureorinstrumenttowhichthe Company  is  a  party  or  by  which  it  is  bound,  or  (iii)  result  in  a  violation  of  any  law,  rule, regulation,order,judgmentordecree(includingfederalandstatesecuritiesorblueskylaws) applicabletotheCompany,exceptinthecaseofclause(ii)above,forsuchconflicts,defaultsor rightswhichwouldnot,individuallyorintheaggregate,reasonablybeexpectedtoresultina Material Adverse Effect. 2.10.    Authorized   Capital.   Schedule   2.10   sets   forth   all   capital   stock   and derivativesecuritiesoftheCompanythatareauthorizedforissuanceandthatareissuedand outstanding.AllissuedandoutstandingsharesofCommonStockhavebeendulyauthorizedand validlyissuedandarefullypaidandnonassessable.TheCompanyhassufficientauthorizedand unissuedsharesofCommonStockasmaybenecessarytoeffecttheissuanceoftheshares issuable  upon  conversion  of  the  Debenture  (the  Shares),  assuming  the  prior  issuance  and exercise,exchangeorconversion,asthecasemaybe,ofallderivativesecuritiesauthorized,as indicated in Schedule 2.10, (subject to a 60 day grace from Closing). 2.11.    Disclosure.   TheCompanyconfirmsthatneitheritnoranyotherperson actingonitsbehalfhasprovidedtheInvestororitsagentsorcounselwithanyinformationthat constitutesorcouldreasonablybeexpectedtoconstitutematerial,nonpublicinformation.   The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 2.12.     Except as listed on Schedule 2.12 hereto, the Company does not have any indebtednessotherthanPermittedLiens.PermittedLiensshallhavethesamemeaningasin the Debenture.  3. RepresentationsandWarrantiesoftheInvestor.TheInvestorherebyrepresents, warrants and covenants that: 3.1.      Authorization.TheInvestorhasfull powerandauthoritytoenterintothis Agreement,   to   perform   its   obligations   hereunder   and   to   consummate   the   transactions contemplatedherebyandhastakenallactionnecessarytoauthorizetheexecutionanddelivery  BN 35285827v1 4  ofthisAgreement,theperformanceofitsobligationshereunderandtheconsummationofthe transactions contemplated hereby. 3.2.      AccreditedInvestorStatus;InvestmentExperience.TheInvestorisan accreditedinvestorasthattermisdefinedinRule501(a)ofRegulationD.TheInvestorcan beartheeconomicriskofitsinvestmentintheDebenture,andhassuchknowledgeand experienceinfinancialandbusinessmattersthatitiscapableofevaluatingthemeritsandrisks of an investment in the Debenture. 3.3.      No Governmental Review.  The Investor understands that no United States federalorstateagencyoranyothergovernmentorgovernmentalagencyhaspassedonormade any  recommendation  or  endorsement  of  the  Debenture  or  the  fairness  or  suitability  of  the investmentintheDebenturenorhavesuchauthoritiespasseduponorendorsedthemeritsofthe offering of the Debenture 3.4.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, validandbindingobligationsoftheInvestorenforceableagainsttheInvestorinaccordancewith theirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneralprinciplesof equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similarlawsrelatingto,oraffectinggenerally,theenforcementofapplicablecreditorsrights and remedies. 3.5.      Ownership of Securities.  The Investor owns and holds, beneficially and of record,theentireright,title,andinterestinandtotheNotesfreeandclearofallrightsandliens (other than pledges orsecurityinterests(x) arisingby operation of applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with its primebrokerageagreementwithsuchbroker).TheInvestorhasfullpowerandauthorityto transferanddisposeoftheNotestotheCompanyfreeandclearofanyrightorlien.Otherthan the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal, orotherrightofanyPersontoacquirealloranypartoftheNotesoranysharesofCommon Stock issuable upon conversion of the Debenture.  4. Additional Covenants 4.1.      Disclosure.TheCompanyshall,onorbefore8:30a.m.,NewYorkNew York time, within four business days after the date of this Agreement, file with the Securities and Exchange  Commission  a  Current  Report  on  Form  8-K  disclosing  all  material  terms  of  the transactions contemplated hereby and attaching the form of this Agreement and the Debenture as exhibits thereto (collectively with all exhibits attached thereto, the 8-K Filing).From and after theissuanceofthe8-KFilingtheInvestorshallnotbeinpossessionofanymaterial,nonpublic informationreceivedfromtheCompanyoranyofitsSubsidiariesoranyoftheirrespective officers,directors,employees,affiliatesoragents,thatisnotdisclosedinthe8-KFiling.   The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, providetheInvestorwithanymaterial,nonpublicinformationregardingtheCompanyfromand  BN 35285827v1 5  afterthefilingofthe8-KFilingwithouttheexpresswrittenconsentoftheInvestor.Tothe extentthattheCompanydeliversanymaterial,non-publicinformationtotheInvestorwithout theInvestorsexpresspriorwrittenconsent,theCompanyherebycovenantsandagreesthatthe InvestorshallnothaveanydutyofconfidentialitytotheCompany,anyofitssubsidiariesorany oftheirrespectiveofficers,directors,employees,affiliatesoragentwithrespectto,oradutyto theCompany,anyofitssubsidiariesoranyoftheirrespectiveofficers,directors,employees, affiliatesoragentornottotradeonthebasisof,suchmaterial,non-publicinformation.   The CompanyshallnotdisclosethenameoftheInvestorinanyfiling,announcement,releaseor otherwise, unless such disclosure is required by law or regulation.  In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similarobligationsunderanyagreement,whetherwrittenororal,betweentheCompany,anyof itssubsidiariesoranyoftheirrespectiveofficers,directors,affiliates,employeesoragents,on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be of nofurtherforceoreffect.TheCompanyunderstandsandconfirmsthattheInvestorwillrelyon the foregoing representations in effecting transactions in securities of the Company. 4.2.      HoldingPeriod.ForthepurposesofSection3(a)(9)andRule144ofthe SecuritiesAct,theCompanyacknowledgesthat(i)theholdingperiodoftheNotesmaybe tackedontotheholdingperiodoftheDebentureaslongasnopaymentismadeinconnection with any conversion, and (ii) the holding period of the Debenture may be tacked onto the holding period of the Shares, and the Company agrees not to take a position contrary to this Section 4.2. 4.3.      Blue Sky.The Company shall make all filings and reports relating to the ExchangerequiredbyRegulationDundertheSecuritiesActandunderapplicablesecuritiesor Blue Sky laws of the states of the United States following the date hereof. 4.4.      Fees and Expenses.  Except as otherwise set forth above, each party to this Agreement  shall  pay  the  fees  and  expenses  of  its  advisers,  counsel,  accountants  and  other experts,  if  any,  and  all  other  expenses  incurred  by  such  party  incident  to  the  negotiation, preparation, execution, delivery and performance of this Agreement.  5. Miscellaneous 5.1.      SuccessorsandAssigns.   Exceptasotherwiseprovidedherein,theterms andconditionsofthisAgreementshallinuretothebenefitofandbebindingupontheparties heretoandtherespectivesuccessorsandassignsoftheparties.NothinginthisAgreement, expressorimplied,isintendedtoconferuponanyparty,otherthanthepartiesheretoortheir respectivesuccessorsandassigns,anyrights,remedies,obligationsorliabilitiesunderorby reason of this Agreement, except as expressly provided in this Agreement. 5.2.      Governing  Law;  Exclusive  Jurisdiction.    All  questions  concerning  the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internallawsoftheStateofNewYork,withoutgivingeffecttoanychoiceoflaworconflictof lawprovisionorrule(whetheroftheStateofNewYorkoranyotherjurisdictions)thatwould causetheapplicationofthelawsofanyjurisdictionsotherthantheStateofNewYork.   Each  BN 35285827v1 6  party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting inNewYorkCounty,NewYork,fortheadjudicationofanydisputehereunderorinconnection herewithorwithanytransactioncontemplatedherebyordiscussedherein,andhereby irrevocablywaives,andagreesnottoassertinanysuit,actionorproceeding,anyclaimthatitis not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought  in  an  inconvenient  forumor  that  thevenue  of  such  suit,  action  or  proceeding  is improper. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 5.3.      Notices.    All  notices,  offers,  acceptance  and  any  other  acts  under  this Agreement(exceptpayment)shallbeinwriting,andshallbesufficientlygivenifdeliveredto theaddresseesinperson,byFedExorsimilarovernightnextbusinessdaydelivery,orbyemail followed by overnight next business day delivery, to the address as provided for on the signature page to this agreement. 5.4.      AmendmentsandWaivers.AnytermofthisAgreementmaybeamended andtheobservanceofanytermofthisAgreementmaybewaived(eithergenerallyorina particularinstanceandeitherretroactivelyorprospectively),onlywiththewrittenconsentofthe Company and the Investor. 5.5.      Severability.IfoneormoreprovisionsofthisAgreementareheldtobe unenforceableunderapplicablelaw,suchprovisionshallbeexcludedfromthisAgreementand the balance of the Agreement shall be interpreted as if such provision were so excluded and shall beenforceableinaccordancewithitstermssolongasthisAgreementassomodifiedcontinues toexpress,withoutmaterialchange,theoriginalintentionsofthepartiesastothesubjectmatter hereofandtheprohibitednature,invalidityorunenforceabilityoftheprovision(s)inquestion doesnotsubstantiallyimpairtherespectiveexpectationsorreciprocalobligationsoftheparties orthepracticalrealizationofthebenefitsthatwouldotherwisebeconferredupontheparties. Thepartieswillendeavoringoodfaithnegotiationstoreplacetheprohibited,invalidor unenforceable  provision(s)  with  a  valid  provision(s),  the  effect  of  which  comes  as  close  as possible to that of the prohibited, invalid or unenforceable provision(s). 5.6.      Counterparts.      This   Agreement   may   be   executed   in   two   or   more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 5.7.      Survival.Therepresentations,warrantiesandcovenantsoftheCompany and the Investor contained herein shall survive the Closing and delivery of the Debenture [SIGNATURES ON THE FOLLOWING PAGE]  BN 35285827v1 7  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. COMPANY: PARALLAX HEALTH SCIENCES, INC. By:   ______________________________________ Name:  Paul Arena Title:    Chief Executive Officer BN 35285827v1  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. INVESTOR: The Corbran, LLC By: Richard Rosenblum Its: Chief Executive Officer By: ________________________________ Name: Richard Rosenblum Title: Chief Executive Officer Address for Notices: ________________________ ________________________ ________________________ Email: ___________________ SSN#: ___________________ BN 35285827v1  EXHIBIT A Debenture [See attached] BN 35285827v1  Schedule I  Note Issuance Date Amount Amount of Debenture  Convertible Note      April 24, 2018 $50,000.00 $63,445.32  Convertible Note      June 14, 2018 $  8,333.00 $10,434.30 BN 35285827v1  Schedule 2.12  Lien Holder Issuance Date Principal Amount of Interest/Penalties  Amount As of 9-30-18  Shahla Melamed* August 14, 2015     $20,550,000 $2,278,281  Internal Revenue Service* Pending $     658,921 $   298,908  State of California, EDD* January 29, 2018    $     125,399 $     65,583 *Related to RoxSan Pharmacy, Inc. subsidiary BN 35285827v1  EXCHANGE AGREEMENT THIS  EXCHANGE  AGREEMENT  (the  Agreement)  is  made  as  of  the  31st  day  of DecemberandeffectiveNovember14,2018,byandbetween,ParallaxHealthSciences,Inc.,a Nevadacorporation,(theCompany)andDigitalPowerLending,LLC,aCalifornialimited liability company (the Investor). WHEREAS, the Investor has previously acquired various securities from the Company in theformofconvertiblenoteswithvariousdatesofissuanceassetforthonScheduleI(the Notes). WHEREAS,  the  Company  has  authorized  a  new  series  of  convertible  debenture  due February28,2019,intheformofExhibitAhereto,whichwillbeconvertibleintosharesofthe Companys Common Stock, par value $0.001. WHEREAS,subjecttothesatisfactionoftheconditionssetforthherein,theCompany andtheInvestordesiretoenterintoatransactionwhereintheCompanyshallissuetheInvestor the debenture intheamountof$221,640.96 (theDebenture) in exchange for each of the Notes as set forth on Schedule I (the Exchange). NOW,THEREFORE,forgoodandvaluableconsideration,thereceiptandsufficiencyof which are hereby acknowledged, the parties agree as follows:  1. Exchange.  The closing of the Exchange (the Closing) will occur on or before December 31, 2018 (or such later date as the parties hereto may agree) following the satisfaction or waiver of the conditions set forth herein (such date, the Closing Date). On the Closing Date, subject to the terms and conditions of this Agreement, the Investor shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the Securities Act), exchange the Notes for the Debenture. At the Closing, the following transactions shall occur (such transactions in this Section 1, the Exchange): 1.1.      OntheClosingDate,theCompanyshallissuetheDebenturetothe Investor.  Promptly  after  the  Closing  Date,  the  Company  shall  deliver  an  executed  original DebenturetotheInvestor.OntheClosingDate,theInvestorshallbedeemedforallcorporate purposestohavebecometheholderofrecordoftheDebentureandshallhavetherightto convert  the  Debenture,  irrespective  of  the  date  the  Company  delivers  the  Debenture  to  the Investor. 1.2.      UponreceiptoftheDebentureinaccordancewithSection1.1,allofthe InvestorsrightsundertheNotesshallbeextinguished(including,withoutlimitation,therights toreceive,asapplicable,anypremium,make-wholeamount,accruedandunpaidinterestor dividendsthereonoranyothersharesofCommonStockwithrespectthereto(whetheruponin connection with a fundamental transaction, event of default or otherwise)). BN 35286565v1  1.3.      TheCompanyandtheInvestorshallexecuteand/ordeliversuchother documentsandagreementsasarecustomaryandreasonablynecessarytoeffectuatethe Exchange. 1.4.      IftheClosinghasnotoccurredonorpriortoDecember31,2018,the Investorshallhavetheright,bydeliveryofwrittennoticetotheCompanytoterminatethis Agreement(suchdate,theTerminationDate).Fromthedatehereofuntiltheearlierof(x)the ClosingDate(asdefinedbelow)and(y)theTerminationDate,theInvestorshallforbearfrom takinganyactionswithrespecttotheNotesnotexplicitlysetforthherein,including,without limitation,conversions,exercises,redemptions,exchangesordeliveryofwrittennoticetothe Company to require the conversion, exercise, redemption or exchange of any of the Notes. 1.5.      It shall be a condition to the obligation of the Investor on the one hand and theCompanyontheotherhand,toconsummatetheExchangecontemplatedhereunderthatthe otherpartysrepresentationsandwarrantiescontainedhereinaretrueandcorrectontheClosing Datewiththesameeffectasthoughmadeonsuchdate,unlesswaivedinwritingbythepartyto whom such representations and warranties are made. 1.6.      At or before the Closing, the Investor shall deliver or cause to be delivered toBuchalterLawFirm,ascounseltotheCompany,(i)theexecutedAgreementand(ii)other items required to effectuate the Exchange.  2. Representations   and   Warranties   of   the   Company.      The   Company   hereby represents and warrants to the Investor that: 2.1.      Concerning the Debenture.     ExceptaslistedonSchedule2.1,thereare nopreemptiverightsofanypersonorentity,rightsoffirstrefusal,participationrights,orother rights to acquire the Debenture. 2.2.      Organization,GoodStandingandQualification.     TheCompanyisa corporationdulyorganized,validlyexistingandingoodstandingunderthelawsoftheStateof Nevada.   TheCompanyisdulyqualifiedtotransactbusinessandisingoodstandingineach jurisdictioninwhichthefailuretosoqualifywouldhaveaMaterialAdverseEffect(asdefined below)onitsbusinessorproperties.AsusedinthisAgreement,MaterialAdverseEffect means  any  material  adverse  effect  on  the  business,  properties,  assets,  liabilities,  operations, resultsofoperations,condition(financialorotherwise)orprospectsoftheCompanyandits Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby orontheExchange(asdefinedbelow)orbytheagreementsandinstrumentstobeenteredinto (or  entered  into)  in  connection  herewith  or  therewith,  or  on  the  authority  or  ability  of  the Company to perform its obligations under this Agreement or the Exchange. 2.3.      Authorization.AllcorporateactiononthepartoftheCompany,its officers, directors and stockholders necessary for the authorization, execution and delivery of this AgreementandtheperformanceofallobligationsoftheCompanyhereunderandthereunder, andtheauthorizationoftheExchange,theissuance(andreservationforissuance)ofthe Debenture have been taken on or prior to the date hereof.  BN 35286565v1 2  2.4.      ValidIssuanceoftheDebenture.     TheDebenturewhenissuedand delivered in accordance with the terms of this Agreement, for the consideration expressed herein, andtheCommonStockwhenissuedinaccordancewiththetermsoftheDebenture,forthe considerationexpressedtherein,willbedulyandvalidlyissued,fullypaidandnon-assessable. UponconversionoftheDebenture,theCommonStockshallbefreelytradableandmaybesold underRule144subjecttotheCompanyhavingfiledallapplicableForm10-Qsandtherequired Form10-K.TheCompanyagreestotakeallactions,including,withoutlimitation,theissuance byitslegalcounselofanynecessarylegalopinions,necessarytoissueunrestrictedCommon StockpursuanttoSection3(a)(9)oftheSecuritiesActandRule144thereunderinconnection withwhichCommonStockissueduponconversionoftheDebentureissuedinexchangeforthe Debenture,theCommonStockwillbefreelytradablewithoutrestrictionandnotcontainingany restrictivelegendwithouttheneedforanyactionbytheInvestorotherthanasrequiredbyRule 144(i)andexecutionoftheapplicablerepresentationletters.Within60daysoftheClosing,the Companyshallhavereservedfromitsdulyauthorizedcapitalstocknotlessthan700%ofthe maximum number of shares of Common Stock issuable upon conversion of the Debenture. 2.5.      ComplianceWithLaws.   TheCompanyhasnotviolatedanylaworany governmentalregulationorrequirementwhichviolationhashadorwouldreasonablybe expectedtohaveaMaterialAdverseEffect,andtheCompanyhasnotreceivedwrittennoticeof any such violation. 2.6.      Consents;  Waivers.    No  consent,  waiver,  approval  or  authority  of  any nature,orotherformalaction,byanyPerson,notalreadyobtained,isrequiredinconnection withtheexecutionanddeliveryofthisAgreementbytheCompanyortheconsummationbythe Company of the transactions provided for herein and therein. 2.7.      AcknowledgmentRegardingInvestorsPurchaseofDebenture.     The CompanyacknowledgesandagreesthattheInvestorisactingsolelyinthecapacityofarms length purchaser with respect to this Agreement and Exchange and the transactions contemplated herebyandtherebyandthattheInvestorisnot(i)anofficerordirectoroftheCompany,(ii)an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), or (iii) to  the  knowledge  of  the  Company,  a  beneficial  owner  of  10%  or  more  of  the  shares  of CommonStock(asdefinedforpurposesofRule13d-3undertheSecuritiesExchangeActof 1934(the Exchange Act).  The Company further acknowledges that the Investor is not acting as afinancialadvisororfiduciaryoftheCompany(orinanysimilarcapacity)withrespecttothe Exchangeandthetransactionscontemplatedherebyandthereby,andanyadvicegivenbythe InvestororanyofitsrepresentativesoragentsinconnectionwiththeExchangeandthe transactions contemplated hereby and thereby is merely incidental to the Investors acceptance of theDebenture.TheCompanyfurtherrepresentstotheInvestorthattheCompanysdecisionto enterintotheExchangehasbeenbasedsolelyontheindependentevaluationbytheCompany and its representatives. 2.8.      AbsenceofLitigation.TotheknowledgeoftheCompany,thereisno action,suit,proceeding,inquiryorinvestigationbeforeorbyanycourt,publicboard, governmentagency,self-regulatoryorganizationorbodypendingor,totheknowledgeofthe Company,  threatened  against  or  affecting  the  Company,  the  Common  Stock,  the  Notes,  the  BN 35286565v1 3  DebentureoranyoftheCompanysofficersordirectorsintheircapacitiesassuch,otherthan what is disclosed in the Companys public filings. 2.9.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validlyauthorized,executedanddeliveredonbehalfoftheCompanyandshallconstitutethe legal,validandbindingobligationsoftheCompanyenforceableagainsttheCompanyin accordancewiththeirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneral principlesofequityortoapplicablebankruptcy,insolvency,reorganization,moratorium, liquidationandothersimilarlawsrelatingto,oraffectinggenerally,theenforcementof applicable  creditors  rights  and  remedies.    The  execution,  delivery  and  performance  by  the CompanyofthisAgreementandtheconsummationbytheCompanyofthetransactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents oftheCompanyor(ii)conflictwith,orconstituteadefault(oraneventwhichwithnoticeor lapseoftimeorbothwouldbecomeadefault)under,orgivetoothersanyrightsoftermination, amendment,accelerationorcancellationof,anyagreement,indentureorinstrumenttowhichthe Company  is  a  party  or  by  which  it  is  bound,  or  (iii)  result  in  a  violation  of  any  law,  rule, regulation,order,judgmentordecree(includingfederalandstatesecuritiesorblueskylaws) applicabletotheCompany,exceptinthecaseofclause(ii)above,forsuchconflicts,defaultsor rightswhichwouldnot,individuallyorintheaggregate,reasonablybeexpectedtoresultina Material Adverse Effect. 2.10.    Authorized   Capital.   Schedule   2.10   sets   forth   all   capital   stock   and derivativesecuritiesoftheCompanythatareauthorizedforissuanceandthatareissuedand outstanding.AllissuedandoutstandingsharesofCommonStockhavebeendulyauthorizedand validlyissuedandarefullypaidandnonassessable.TheCompanyhassufficientauthorizedand unissuedsharesofCommonStockasmaybenecessarytoeffecttheissuanceoftheshares issuable  upon  conversion  of  the  Debenture  (the  Shares),  assuming  the  prior  issuance  and exercise,exchangeorconversion,asthecasemaybe,ofallderivativesecuritiesauthorized,as indicated in Schedule 2.10, (subject to a 60 day grace from Closing). 2.11.    Disclosure.   TheCompanyconfirmsthatneitheritnoranyotherperson actingonitsbehalfhasprovidedtheInvestororitsagentsorcounselwithanyinformationthat constitutesorcouldreasonablybeexpectedtoconstitutematerial,nonpublicinformation.   The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 2.12.     Except as listed on Schedule 2.12 hereto, the Company does not have any indebtednessotherthanPermittedLiens.PermittedLiensshallhavethesamemeaningasin the Debenture.  3. RepresentationsandWarrantiesoftheInvestor.TheInvestorherebyrepresents, warrants and covenants that: 3.1.      Authorization.TheInvestorhasfull powerandauthoritytoenterintothis Agreement,   to   perform   its   obligations   hereunder   and   to   consummate   the   transactions contemplatedherebyandhastakenallactionnecessarytoauthorizetheexecutionanddelivery  BN 35286565v1 4  ofthisAgreement,theperformanceofitsobligationshereunderandtheconsummationofthe transactions contemplated hereby. 3.2.      AccreditedInvestorStatus;InvestmentExperience.TheInvestorisan accreditedinvestorasthattermisdefinedinRule501(a)ofRegulationD.TheInvestorcan beartheeconomicriskofitsinvestmentintheDebenture,andhassuchknowledgeand experienceinfinancialandbusinessmattersthatitiscapableofevaluatingthemeritsandrisks of an investment in the Debenture. 3.3.      No Governmental Review.  The Investor understands that no United States federalorstateagencyoranyothergovernmentorgovernmentalagencyhaspassedonormade any  recommendation  or  endorsement  of  the  Debenture  or  the  fairness  or  suitability  of  the investmentintheDebenturenorhavesuchauthoritiespasseduponorendorsedthemeritsofthe offering of the Debenture 3.4.      Validity;Enforcement;NoConflicts.ThisAgreementhasbeendulyand validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, validandbindingobligationsoftheInvestorenforceableagainsttheInvestorinaccordancewith theirrespectiveterms,exceptassuchenforceabilitymaybelimitedbygeneralprinciplesof equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similarlawsrelatingto,oraffectinggenerally,theenforcementofapplicablecreditorsrights and remedies. 3.5.      Ownership of Securities.  The Investor owns and holds, beneficially and of record,theentireright,title,andinterestinandtotheNotesfreeandclearofallrightsandliens (other than pledges orsecurityinterests(x) arisingby operation of applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with its primebrokerageagreementwithsuchbroker).TheInvestorhasfullpowerandauthorityto transferanddisposeoftheNotestotheCompanyfreeandclearofanyrightorlien.Otherthan the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal, orotherrightofanyPersontoacquirealloranypartoftheNotesoranysharesofCommon Stock issuable upon conversion of the Debenture.  4. Additional Covenants 4.1.      Disclosure.TheCompanyshall,onorbefore8:30a.m.,NewYorkNew York time, within four business days after the date of this Agreement, file with the Securities and Exchange  Commission  a  Current  Report  on  Form  8-K  disclosing  all  material  terms  of  the transactions contemplated hereby and attaching the form of this Agreement and the Debenture as exhibits thereto (collectively with all exhibits attached thereto, the 8-K Filing).From and after theissuanceofthe8-KFilingtheInvestorshallnotbeinpossessionofanymaterial,nonpublic informationreceivedfromtheCompanyoranyofitsSubsidiariesoranyoftheirrespective officers,directors,employees,affiliatesoragents,thatisnotdisclosedinthe8-KFiling.   The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, providetheInvestorwithanymaterial,nonpublicinformationregardingtheCompanyfromand  BN 35286565v1 5  afterthefilingofthe8-KFilingwithouttheexpresswrittenconsentoftheInvestor.Tothe extentthattheCompanydeliversanymaterial,non-publicinformationtotheInvestorwithout theInvestorsexpresspriorwrittenconsent,theCompanyherebycovenantsandagreesthatthe InvestorshallnothaveanydutyofconfidentialitytotheCompany,anyofitssubsidiariesorany oftheirrespectiveofficers,directors,employees,affiliatesoragentwithrespectto,oradutyto theCompany,anyofitssubsidiariesoranyoftheirrespectiveofficers,directors,employees, affiliatesoragentornottotradeonthebasisof,suchmaterial,non-publicinformation.   The CompanyshallnotdisclosethenameoftheInvestorinanyfiling,announcement,releaseor otherwise, unless such disclosure is required by law or regulation.  In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similarobligationsunderanyagreement,whetherwrittenororal,betweentheCompany,anyof itssubsidiariesoranyoftheirrespectiveofficers,directors,affiliates,employeesoragents,on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be of nofurtherforceoreffect.TheCompanyunderstandsandconfirmsthattheInvestorwillrelyon the foregoing representations in effecting transactions in securities of the Company. 4.2.      HoldingPeriod.ForthepurposesofSection3(a)(9)andRule144ofthe SecuritiesAct,theCompanyacknowledgesthat(i)theholdingperiodoftheNotesmaybe tackedontotheholdingperiodoftheDebentureaslongasnopaymentismadeinconnection with any conversion, and (ii) the holding period of the Debenture may be tacked onto the holding period of the Shares, and the Company agrees not to take a position contrary to this Section 4.2. 4.3.      Blue Sky.The Company shall make all filings and reports relating to the ExchangerequiredbyRegulationDundertheSecuritiesActandunderapplicablesecuritiesor Blue Sky laws of the states of the United States following the date hereof. 4.4.      Fees and Expenses.  Except as otherwise set forth above, each party to this Agreement  shall  pay  the  fees  and  expenses  of  its  advisers,  counsel,  accountants  and  other experts,  if  any,  and  all  other  expenses  incurred  by  such  party  incident  to  the  negotiation, preparation, execution, delivery and performance of this Agreement.  5. Miscellaneous 5.1.      SuccessorsandAssigns.   Exceptasotherwiseprovidedherein,theterms andconditionsofthisAgreementshallinuretothebenefitofandbebindingupontheparties heretoandtherespectivesuccessorsandassignsoftheparties.NothinginthisAgreement, expressorimplied,isintendedtoconferuponanyparty,otherthanthepartiesheretoortheir respectivesuccessorsandassigns,anyrights,remedies,obligationsorliabilitiesunderorby reason of this Agreement, except as expressly provided in this Agreement. 5.2.      Governing  Law;  Exclusive  Jurisdiction.    All  questions  concerning  the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internallawsoftheStateofNewYork,withoutgivingeffecttoanychoiceoflaworconflictof lawprovisionorrule(whetheroftheStateofNewYorkoranyotherjurisdictions)thatwould causetheapplicationofthelawsofanyjurisdictionsotherthantheStateofNewYork.   Each  BN 35286565v1 6  party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting inNewYorkCounty,NewYork,fortheadjudicationofanydisputehereunderorinconnection herewithorwithanytransactioncontemplatedherebyordiscussedherein,andhereby irrevocablywaives,andagreesnottoassertinanysuit,actionorproceeding,anyclaimthatitis not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought  in  an  inconvenient  forumor  that  thevenue  of  such  suit,  action  or  proceeding  is improper. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 5.3.      Notices.    All  notices,  offers,  acceptance  and  any  other  acts  under  this Agreement(exceptpayment)shallbeinwriting,andshallbesufficientlygivenifdeliveredto theaddresseesinperson,byFedExorsimilarovernightnextbusinessdaydelivery,orbyemail followed by overnight next business day delivery, to the address as provided for on the signature page to this agreement. 5.4.      AmendmentsandWaivers.AnytermofthisAgreementmaybeamended andtheobservanceofanytermofthisAgreementmaybewaived(eithergenerallyorina particularinstanceandeitherretroactivelyorprospectively),onlywiththewrittenconsentofthe Company and the Investor. 5.5.      Severability.IfoneormoreprovisionsofthisAgreementareheldtobe unenforceableunderapplicablelaw,suchprovisionshallbeexcludedfromthisAgreementand the balance of the Agreement shall be interpreted as if such provision were so excluded and shall beenforceableinaccordancewithitstermssolongasthisAgreementassomodifiedcontinues toexpress,withoutmaterialchange,theoriginalintentionsofthepartiesastothesubjectmatter hereofandtheprohibitednature,invalidityorunenforceabilityoftheprovision(s)inquestion doesnotsubstantiallyimpairtherespectiveexpectationsorreciprocalobligationsoftheparties orthepracticalrealizationofthebenefitsthatwouldotherwisebeconferredupontheparties. Thepartieswillendeavoringoodfaithnegotiationstoreplacetheprohibited,invalidor unenforceable  provision(s)  with  a  valid  provision(s),  the  effect  of  which  comes  as  close  as possible to that of the prohibited, invalid or unenforceable provision(s). 5.6.      Counterparts.      This   Agreement   may   be   executed   in   two   or   more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 5.7.      Survival.Therepresentations,warrantiesandcovenantsoftheCompany and the Investor contained herein shall survive the Closing and delivery of the Debenture [SIGNATURES ON THE FOLLOWING PAGE]  BN 35286565v1 7  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. COMPANY: PARALLAX HEALTH SCIENCES, INC. By:   ______________________________________ Name:  Paul Arena Title:    Chief Executive Officer BN 35286565v1  IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above. INVESTOR: Digital Power Lending, LLC By: William Corbett Its: President By: ________________________________ Name: William Corbett Title: President Address for Notices: ________________________ ________________________ ________________________ Email: ___________________ SSN#: ___________________ BN 35286565v1  EXHIBIT A Debenture [See attached] BN 35286565v1  Schedule I  Note Issuance Date Amount Amount of Debenture  Convertible Note      April 24, 2018 $150,000.00 $190,336.98  Convertible Note      June 14, 2018 $  25,000.00 $  31,303.98 BN 35286565v1  Schedule 2.12  Lien Holder Issuance Date Principal Amount of Interest/Penalties  Amount As of 9-30-18  Shahla Melamed* August 14, 2015     $20,550,000 $2,278,281  Internal Revenue Service* Pending $     658,921 $   298,908  State of California, EDD* January 29, 2018    $     125,399 $     65,583 *Related to RoxSan Pharmacy, Inc. subsidiary BN 35286565v1